One has found an important cell cycle controller. This guard can decide the cell cycle toward proliferation or quiescence. Cyclindependent kinase 2 (CDK2) is a unique target among the CDK family in melanoma therapy. We attempted to find out TCM compounds from TCM Database@Taiwan that have the ability to inhibit the activity of CDK2 by systems biology. We selected Tetrahydropalmatine, Reserpiline, and (+)-Corydaline as the candidates by docking and screening results for further survey. We utilized support vector machine (SVM), multiple linear regression (MLR) models and Bayesian network for validation of predicted activity. By overall analysis of docking results, predicted activity, and molecular dynamics (MD) simulation, we could conclude that Tetrahydropalmatine, Reserpiline, and (+)-Corydaline had better binding affinity than the control. All of them had the ability to inhibit the activity of CDK2 and might have the opportunity to be applied in melanoma therapy.
Introduction
One has discovered an important cell cycle controller. This gatekeeper can decide the cell cycle toward proliferation or quiescence [1] . The cell cycle means division and duplication of the cells. If the process occurs in prokaryotes, it is termed binary fission. In eukaryotes, the process can consist of interphase and mitotic (M) phase. The interphase can be further divided into G1 (gap 1) phase, S (synthesis) phase, and G2 phase [2, 3] . Normal cell cycle follows the ordinary steps, but cancer cells grow without regulation. The rate of progress in cell cycle is decided by cyclins and cyclin-dependent kinases (CDKs). Entering of each phase is controlled by specific cyclin-CDK complex. CDK is a member of serine-threonine kinase family because a cyclin binds to a CDK and starts the phosphorylation of its serine and threonine site [4, 5] . Cyclin controls the activity of CDK. In other words, CDK is like the engine in a car, and cyclin is like the gearbox. Cyclin E-CDK2 complex guides the process from G1 to S phase, while cyclin A-CDK2 complex is required to pass through the S phase [6, 7] . Related efforts let Hartwell et al., Bandara et al., and Nurse win the Nobel Prize in Physiology or Medicine 2001 [8] [9] [10] .
As mention to inhibitory mechanism, the genes of kinase inhibitory protein/CDK interacting protein (kip/cip) family prevent the progression of the cell cycle. Because these proteins are produced in prevention of tumor formation, they are known as tumor suppressors. The kip/cip gene family includes the genes p21, p27, and p57. These proteins arrest cell cycle in G 1 phase by binding to cyclin-CDK complexes and inactivating them. P21, encoded by the CDKN1A gene, is activated by p53 which plays a role in apoptosis; p27, encoded by the CDKN1B gene, is activated by transforming growth factor (TGF ) which is a growth inhibitor; p57, encoded by the CDKN1C gene, is a negative regulator of cell proliferation [11] [12] [13] [14] [15] . Cancer cells are loss of cell cycle rhythm. CDK2 is encoded by CDK2 gene as a downstream product of microphthalmia-associated transcription factor (MITF) in melanocytes, too. MITF is essential for development of embryonic melanocytes and even malignant melanoma [16] . CDK2 has an important role in the occurrence and progression of melanoma among its CDK family. Inhibition of CDK2 significantly reduced growth of melanoma cells [17] . These researches have told us that CDK2 would be a unique target rather than other CDKs in melanoma therapy.
Malignant melanoma is very dangerous if it is not diagnosed and treated early. It causes high mortality rate [18] . Gold standard of primary melanoma is surgery; but combined therapy, such as chemotherapy, immunotherapy, or radiotherapy, is necessary to advanced or metastatic melanoma [19, 20] . The Raf protein/mitogen-activated protein kinase/extracellular-signal-regulated kinase (RAF/MAPK/ ERK) signal pathway has thus become a molecular target for therapeutic design of advanced melanoma harboring the B-RAF gene mutation [21, 22] . However, not every melanoma lesion carries this gene mutation. In addition, resistance to RAF inhibitors has been reported recently [23] [24] [25] [26] . Besides melanoma, CDK2 is also overexpressed in other tumors [27, 28] . One study has demonstrated a significant increase of cyclin E and CDK2 expression during tumor progression in malignant melanoma compared to benign melanocytic lesions [29] . Previous studies had demonstrated that Dinaciclib was a CDK1/2/5/9 inhibitor leading to tumor apoptosis via p53 expression [30, 31] .
In this study, we aimed to determine the small molecules binding and inhibiting the function of CDK2 that would be an effective method to interfere with the aggressive biological behavior of advanced melanoma. Knowing the mechanism of various diseases provides us with the new direction to resolve them [32, 33] . Modern technology in medicine helps us be more confident in managing troublesome diseases [34] . Computational simulation has rapidly emerged in small molecular drug design [35] [36] [37] [38] . Traditional Chinese Medicine (TCM) has mild features, and it has therapeutic effect in series of diseases [39] [40] [41] . Application of TCM database lets it become possible to find out drug-like molecules [42] [43] [44] . In this purpose, we attempted to find out candidate compounds from the largest TCM Database@Taiwan (http://tcm .cmu.edu.tw/) in the world that have the ability to inhibit the activity of CDK2 [45] .
Materials and Methods

Docking and Candidate
Screening. All small molecular compounds were downloaded from TCM Database@Taiwan (http://tcm.cmu.edu.tw/) to identify potential CDK2 inhibitor screening [45] . Cyclin-dependent kinase 2 (CDK2) protein data and structure were obtained from the Uniprot Knowledgebase (CDK2 Human, P24941) and Protein Data Bank (PDB ID: 1URW). The resolution of its crystal structure was from residue 1 to 298, and key residues of the binding sites are located at Lys33, Asp86, Asp127, Asn132, and Asp145 [46] . PONDR-FIT program in the DisProt website was employed to exclude the disordered residues of 3D structure of CDK2 [47, 48] . This experiment utilized the LigandFit program of Discovery Studio (DS) 2.5 to filter out the small molecules from TCM database that could dock with CDK2 binding sites. All the small molecules for virtual screening had passed through Lipinski's Rule of Five, absorption, distribution, metabolism, excretion, and toxicity (ADMET), to rule out potential toxic compounds in DS 2.5 [49, 50] . The locations of binding sites were originally at the ligand, imidazo (1,2- 
, binding with CDK2 crystal structure. All the poses of small molecules in docking process were minimized by the force field of Chemistry at HARvard Macromolecular Mechanics (CHARMm) [51] . We also adopted the LIGPLOT program to illustrate hydrogen bond (H-bond) and hydrophobic contact between the ligand and CDK2 protein [52, 53] .
Support Vector Machine (SVM), Multiple Linear
Regression (MLR) Models, and Bayesian Network. We obtained 27 compounds and pIC50 data of CDK2 inhibitors from the study of Tripathi et al. [54] . Then we drew 2D and 3D structure of these compounds by ChemBioDraw software. Then we utilized Genetic Function Approximation (GFA) algorithm in DS 2.5 to find the appropriate molecular descriptors [41, 55] . The descriptors constructing multiple linear regression (MLR) and support vector machine (SVM) models were validated by Matlab Statistics Toolbox and libSVM. The description normalized between [−1, +1] by SVM training model. We utilized the activity of square correlation coefficient ( 2 ) to validate each model. The data of these compounds was adopted for predicting the control and top 3 candidate compounds. We utilized fivefold cross validation and chose the highest 2 of SVM and MLR to perform activity prediction models.
For a well-defined Bayesian network, our algorithm was used in Matlab codes that integrated the Bayes Net Toolbox (BNT) package and the Banjo package to predict pIC50 value. The physiochemical properties relating to the binding strength were extracted as descriptors by DS 2.5.
Molecular Dynamics (MD) Simulation.
We utilized GROningen MAchine for Chemical Simulations (GRO-MACS) 4.0.733 for MD simulation of the candidates and the control compound [56] . Minimization, heating, equilibration, and production were the four phases for selected protein-ligand complex simulation. We analyzed the trajectory figures of root mean square deviation (RMSD), Gyrate, mean square deviation (MSD), and solvent accessible surface area (SASA). We illustrated each ligand and its corresponding protein change for the 3 candidates and the control. Total energy, root mean square fluctuation (RMSF), RMSD matrix and clustering diagram, and secondary structure changes were adopted to compare the changes of the 3 candidates and the control during MD [57] . We calculated distance of hydrogen bond (H-bond) and its stability by torsion analysis between the ligand and essential amino acids of CDK2. Best distance of H-bond was set at 0.3 nm or 3Å. CAVER software was adopted to analyze all possible pathways when the ligand bound with CDK2 protein [58] . The parameters were time sparsity 1; first frame 0; last frame 100; probe radius 0.9, shell radius 4, shell depth 5.
Results and Discussion
Docking and Candidate Screening.
All the regions for key residues (Lys33 to Asp145) of CDK2 protein recorded in the literature did not locate at the disordered region. We could prove that the 3D structure of CDK2 (PDB ID: 1URW) was reliable ( Figure 1 ). Table 1 listed dock score, H-bond forming residues, H-bond quantity, SVM, MLR, and BNT of the top 10 TCM compounds ranked by dock score. We selected Tetrahydropalmatine, Reserpiline, and (+)-Corydaline as the candidates for further examination. Dinaciclib, the CDK2 inhibitor, was assigned as the control compound in this study. Tetrahydropalmatine, Reserpiline, and (+)-Corydaline were mainly extracted from Phellodendron amurense, Rauwolfia serpentina, and Corydalis yanhusuo, respectively. The literature had proved that the original plants of top 3 compounds had antitumor efficacy [59] [60] [61] [62] . Therefore, we believed that the top 3 candidate compounds had the potential role in the inhibition of tumor growth. The structure of top 3 TCM compounds and control compound was shown in Figures 2(a)-2(c) and 2(d). The candidate compounds which had good affinity with binding sites according to scoring function may be associated with H-bond, charge interaction, bond, van der Waals forces, and hydrophobic contact. We illustrated how the top 3 and control compounds interacted with the binding sites of target protein. All the top 3 candidate compounds bound to Asp86 and Lys89 residues and formed charge interaction with Asp86. The phenomenon was consistent with the key residues described in the literature. According to this finding, Asp86 and Lys89 residues were important binding sites. and control compounds formed hydrophobic contact with at least 3 amino acid residues, respectively. The same amino acid residue was Thr160. Tetrahydropalmatine, Reserpiline, and control compound formed hydrophobic contact with Leu134. Reserpiline and (+)-Corydaline formed hydrophobic contact with Ile10, too. Although control compound did not form Hbond with any key residue, it formed hydrophobic contact with Asp86 and Asn132 (Figure 4) .
Based on the results of docking, we concluded that candidate compounds had more stable force than control compound. The hydrophobic contact of candidate compounds was less than control compound, but all of them formed hydrophobic contact with amino acid residue Thr160. The analytic result of binding sites was compatible with the trend in dock score (Table 1) . We proved that Asp86 was important in the binding site again.
Support Vector Machine (SVM), Multiple Linear Regression (MLR) Models, and Bayesian Network.
We selected the following 7 optimum descriptors for predicting activities: ALogP, Num Hydrogens, Molecular Volume, CHI 3 C, CHI V 3 C, JY, and Jurs RPSA. We employed these descriptors for constructing SVM, MLR models, and Bayesian network. For the 7 descriptors in this study, each set of ligandcompound discrete data allowed us to estimate complex relationships, the descriptors, and the binding strength, without hypothesis of data distribution that may bias the Bayesian network inference model. Using these descriptors, the predictive models were generated as follows: p(IC50) = −10.551 − 0.406 * ALogP − 0.776 * Num Hydrogens + 0.095 * Molecular Volume + 5.280 * CHI 3 C − 2.794 * CHI V 3 C + 6.356 * JY − 40.920 * Jurs RPSA. For this purpose, we discretized the data of pIC50 and these descriptors from continuous values into various categories on the basis of their distribution property. The 27 ligands of CDK2 inhibitors were randomly divided into 20 training sets and 7 test sets for validation. The 2 for predicted biological activity of SVM, MLR, and Bayesian network were 0.9207, 0.9124, and 0.6538, respectively. These results suggested that predicted activity of any given compound was almost consistent with observed activity. SVM of Tetrahydropalmatine, Reserpiline, and (+)-Corydaline were 6.233, 7.148, and 6.217. MLR of the 3 candidates were 6.156, 6.044, and 6.283. BNT of the 3 candidates were 6.509, 6.995, and 6.499. SVM, MLR, and BNT of the control were 6.405, 3.229, and 6.899. Predicted activities of the 3 candidates were almost the same as or better than the control ( Figure 5 ).
Molecular Dynamics (MD) Simulation.
We drew the trajectories of ligand and protein RMSD to show the deviation of each ligand and its corresponding protein during the period of MD. Interestingly, (+)-Corydaline had large deviation at 11 ns of MD, but it became stable after the large deviation. In contrast, Tetrahydropalmatine and Reserpiline were stable during the whole period of MD. However, the control was unstable during the whole period of MD. In contrast to ligand RMSD, protein RMSD of the 3 candidates and the control were relatively stable after 6 ns of MD. (+)-Corydaline corresponding protein had the largest mean RMSD value, and Tetrahydropalmatine corresponding protein had the smallest mean RMSD value. We concluded that the 3 candidates could bind with CDK2 more stably than the control (Figure 6(a) ). control were stable during the whole period of MD. In contrast to ligand SASA, protein SASA of the 3 candidates and the control were fluctuated during the whole period of MD. It was evident that all the 3 candidates and the control could induce surface change of CDK2 (Figure 6(d) ). According to the figures of RMSD, Gyrate, MSD, and SASA, we concluded that the 3 candidates could bind with CDK2 and induce its conformational change the same as or even more stable than the control.
We illustrated total energy to observe the binding energy stability for the ligand and protein. We illustrated distance of H-bond between the ligand and essential amino acids of CDK2 to discuss the binding force between the ligand and protein. According to occupancy of H-bond between the ligands and CDK2 protein, the ligands formed H-bonds with several residues of CDK2 protein permanently or temporarily. We picked up different patterns of distance of H-bond in the following description which did The control formed H-bond with Asp86, Lys89, and Gln131 of CDK2 unstably during MD (Figure 11(d) ). H-bond was important binding force between the ligand and protein.
Based on these changes, we could discover that all the candidates and the control formed H-bonds with essential amino acids in quite different patterns. The change in ligand torsion during MD also provided important clues to the stability of the H-bond. Tetrahydropalmatine formed 2 H-bonds with Lys89 of CDK2 as shown in Figures 3(a) and 4(a) . The torsion angles 1 and 2 the control were near residues 40 and 160. The findings of secondary structure changes were similar to that of RMSF. There were larger changes near residues 40 and 160, too ( Figure 13) . We speculated that all the 3 candidates and the control bound with CDK2 protein successfully and inhibited the activity of CDK2 by inducing its structural component change. We illustrated 3D simulation of ligand pathway to analyze all possible pathways when the ligand bound with CDK2 protein. There were 4 possible pathways for Tetrahydropalmatine or Reserpiline. However, there were 6 and 10 possible pathways for (+)-Corydaline and Dinaciclib, respectively (Figure 14 ).
Conclusion
One has found an important cell cycle controller. This guard can decide the cell cycle toward proliferation or quiescence.
Normal cells follow the ordinary cycle, but cancer cells grow without rhythm. The rate of progress in cell cycle is regulated by cyclins and cyclin-dependent kinases (CDKs). CDK2 is a unique target among the CDK family in melanoma therapy. Previous studies had demonstrated that Dinaciclib was a CDK1/2/5/9 inhibitor leading to tumor apoptosis. We attempted to find out TCM compounds from the largest TCM Database@Taiwan in the world that have the ability to inhibit the activity of CDK2 by computational simulation.
We selected Tetrahydropalmatine, Reserpiline, and (+)-Corydaline as the candidates by docking and candidate screening results for further validation. Dinaciclib was assigned as the control compound. All the 3 candidates were better than the control in terms of docking score. Asp86 and Thr160 were the key residues for the 3 candidates and the control according to docking poses. All the 3 candidates were enrolled in constructing predicted activity using SVM, MLR models, and Bayesian network. These constructed models were reliable due to high 2 values. The results suggested that predicted activity of any given compound was almost consistent with observed activity. Predicted activities of the 3 candidates were almost the same as or better than the control based on SVM, MLR, and BNT values.
MD simulation provided very useful information about the dynamic changes when the ligands bound with CDK2 protein. According to the figures of RMSD, Gyrate, MSD, and SASA, we concluded that the 3 candidates could bind with CDK2 and induce its conformational change the same as or even more stable than the control. Based on total energy and RMSF, we concluded that all the 3 candidates and the control bound with CDK2 protein stably but caused different fluctuation in individual residues. The MD poses of 0 ns and snapshot after 19 ns were compared with docking poses of ligand and protein. The results let us know the interesting change of binding sites during MD. We illustrated distance of H-bond and torsion analysis to observe how the important binding force affected the connection between the ligand and CDK2 protein. There were many interesting findings which had been described in the paper. The results of secondary structure changes were similar to that of RMSF. We speculated that all the 3 candidates and the control bound with CDK2 protein successfully and inhibited the activity of CDK2 by inducing its structural component change. Finally, 3D simulation of ligand pathway told us that there were many possible pathways when the ligand bound with CDK2 protein.
By overall analysis of docking results, predicted activity, and MD simulation, we could conclude that Tetrahydropalmatine, Reserpiline, and (+)-Corydaline had better binding affinity than Dinaciclib. All of them had the ability to inhibit the activity of CDK2 and might have the opportunity to be used in melanoma therapy. 
